13 results match your criteria Clinical Medicine Insights: Urology [Journal]

  • Page 1 of 1

Urologic chronic pelvic pain syndrome: insights from the MAPP Research Network.

Nat Rev Urol 2018 Dec 18. Epub 2018 Dec 18.

Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine at The University of Pennsylvania, Philadelphia, PA, USA.

Urologic chronic pelvic pain syndrome (UCPPS), which encompasses interstitial cystitis/bladder pain syndrome and chronic prostatitis/chronic pelvic pain syndrome, is characterized by chronic pain in the pelvic region or genitalia that is often accompanied by urinary frequency and urgency. Despite considerable research, no definite aetiological risk factors or effective treatments have been identified. The Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Research Network uses a novel integrated strategy to characterize UCPPS as a systemic disorder that potentially involves multiple aetiologies. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41585-018-0135-5
Publisher Site
http://dx.doi.org/10.1038/s41585-018-0135-5DOI Listing
December 2018
11 Reads

Antimuscarinic Use in Men Treated With Bladder Outlet Obstruction Medication Therapy.

Urology 2018 Dec 8;122:76-82. Epub 2018 Sep 8.

SSM Health, Department of Clinical Analytics and Insights, St. Louis, MO.

Objective: To assess changes over time in the use of antimuscarinics (AM) among visits in adult men treated with bladder outlet obstruction (BOO) medication therapy (ie, alpha blocker and 5-alpha reductase inhibitors).

Methods: We used the National Ambulatory Medicare Care Survey database (2006-2014) to identify men aged 40 or older, who initiated or continued on BOO medication therapy. Among these visits, we assessed the percentage of AM and evaluated trends of AM use across between 2006 and 2014 using multivariable logistic regression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urology.2018.08.039DOI Listing
December 2018
7 Reads

Three-dimensional Printing and Augmented Reality: Enhanced Precision for Robotic Assisted Partial Nephrectomy.

Urology 2018 06 22;116:227-228. Epub 2018 May 22.

Division of Urologic Oncology, Department of Urology, New York University Langone Medical Center, New York, NY.

Objective: To describe novel 3-dimensional (3D) printing and augmented reality (AR) methods of image data visualization to facilitate anatomic understanding and to assist with surgical planning and decision-making during robotic partial nephrectomy.

Materials And Methods: We created a video of the workflow for creating 3D printed and AR kidney models along with their application to robotic partial nephrectomy. Key steps in their development are (1) radiology examination (magnetic resonance imaging and computed tomography), (2) image segmentation, (3) preparing for 3D printing or AR, and (4) printing the model or deploying the model to the AR device. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urology.2017.12.038DOI Listing
June 2018
4 Reads

Integration and utilization of modern technologies in nephrolithiasis research.

Nat Rev Urol 2016 09 23;13(9):549-57. Epub 2016 Aug 23.

Department of Urology, Indiana University Health at Methodist Hospital, 1801 Senate Boulevard #220, Indianapolis, Indianapolis 46202, USA.

Nephrolithiasis, or stones, is one of the oldest urological diseases, with descriptions and treatment strategies dating back to ancient times. Despite the enormous number of patients affected by stones, a surprising lack of conceptual understanding of many aspects of this disease still exists. This lack of understanding includes mechanisms of stone formation and retention, the clinical relevance of different stone compositions and that of formation patterns and associated pathological features to the overall course of the condition. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrurol.2016.148DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5880530PMC
September 2016
10 Reads

Differential proteomic profiling of spermatozoal proteins of infertile men with unilateral or bilateral varicocele.

Urology 2015 Mar;85(3):580-8

Department of Urology, the Center for Reproductive Medicine, Glickman Urological & Kidney Institute, Cleveland Clinic, Cleveland, OH.

Objective: To compare the sperm protein profile between infertile men with unilateral varicocele and infertile men with bilateral varicocele.

Methods: This prospective study investigated 50 infertile patients with clinical varicocele (33 unilateral and 17 bilateral) seeking fertility workup between March 2012 and April 2014. Routine sperm parameters, reactive oxygen species, total antioxidant capacity, and sperm deoxyribonucleic acid fragmentation were assessed in their semen. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urology.2014.11.030DOI Listing
March 2015
13 Reads
2 Citations
2.190 Impact Factor

Clinical Evaluation of Abiraterone in the Treatment of Metastatic Prostate Cancer.

Clin Med Insights Urol 2013 Jul;2013(7):1-14

Assistant Professor of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore MD.

Treatment of castration-resistant prostate cancer remains an area of unmet medical need. Evidence suggests that this entity continues to be driven by androgens and androgen receptor (AR) signaling. Abiraterone acetate, a pregnenolone derivative, is an oral selective and irreversible inhibitor of the key steroidogenic enzyme CYP17. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4137/CMU.S8337DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3904375PMC
July 2013
9 Reads

Does benign prostatic tissue contribute to measurable PSA levels after radical prostatectomy?

Urology 2009 Jul 5;74(1):167-70. Epub 2009 May 5.

Division of Urologic Oncology, Department of Urology, New York University School of Medicine, New York, New York 10016, USA.

Objectives: To provide insights into the likelihood that benign prostatic tissue represents a source of measurable prostate-specific antigen (PSA) after radical prostatectomy.

Methods: From October 2000 to December 2006, 1308 consecutive men underwent open radical retropubic prostatectomy by a single surgeon. Of these 1308 men, 331 (25. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urology.2008.07.067DOI Listing
July 2009
9 Reads

Prostate tissue androgens: history and current clinical relevance.

Urology 2008 Aug 27;72(2):247-54. Epub 2008 May 27.

Department of Urology, University of California, Los Angeles, Geffen School of Medicine, Los Angeles, California, USA.

Direct determination of androgen levels in prostate tissue provides a perspective on the organ that is not available via androgen serum levels. The principle prostatic androgens, primarily dihydrotestosterone (DHT) and secondarily testosterone, can be readily assayed in quick-frozen prostate biopsy cores or surgical specimens. Such assays have proved important in establishing (1) that DHT is a permissive factor in BPH pathogenesis, (2) a mechanism for the treatment of BPH, (3) an understanding of prostate cancer chemoprevention, (4) an explanation for the 'escape' of prostate cancer from castration therapy, (5) prostate safety of testosterone replacement therapy, and (6) insights into the cause of racial differences of prostate cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urology.2008.03.033DOI Listing
August 2008
10 Reads

Biology of prostate-specific antigen.

Authors:
Hans Lilja

Urology 2003 Nov;62(5 Suppl 1):27-33

Department of Laboratory Medicine, Division of Clinical Chemistry, Lund University, University Hospital (UMAS), Malmö, Sweden.

The human kallikrein (hk) family, located on chromosome 19, encodes prostate-specific antigen (PSA [or hK3]), hK2, hK4, and hK15 (prostin), as well as other serine proteases. Although PSA has been used in the detection of prostate cancer for several years, much remains unknown about its function and forms. The regulatory mechanisms of PSA are vital to its understanding. Read More

View Article

Download full-text PDF

Source
November 2003
8 Reads

Interstitial cystitis: a chronic visceral pain syndrome.

Authors:
U Wesselmann

Urology 2001 Jun;57(6 Suppl 1):32-9

the Johns Hopkins University School of Medicine, Department of Neurology, Blaustein Pain Treatment Center, Baltimore, Maryland 21205, USA.

Interstitial cystitis (IC) has remained an unresolved problem in clinical urology. The etiology and pathophysiologic mechanisms of IC are still undetermined, and to date the diagnosis is based on the clinical characteristics of the disease and the exclusion of other diseases and pathology that can mimic the symptoms of IC. In clinical practice, much emphasis has been placed on finding a specific etiology and specific pathologic markers for the disease and on identifying specific events that precipitate IC; however, those have not been identified with certainty. Read More

View Article

Download full-text PDF

Source
June 2001
11 Reads

Anastomotic strictures following radical prostatectomy: insights into incidence, effectiveness of intervention, effect on continence, and factors predisposing to occurrence.

Urology 2001 Apr;57(4):742-6

Department of Urology, Division of Biostatistics, New York University School of Medicine, New York, New York, USA.

Objectives: To examine the incidence, effectiveness of intervention, effect on continence, and factors predisposing to the occurrence of anastomotic strictures following radical retropubic prostatectomy.

Methods: Between January 1994 and June 1999, 753 radical retropubic prostatectomies were performed by a single surgeon. Anastomotic strictures were managed by dilatation followed by a self-catheterization regimen. Read More

View Article

Download full-text PDF

Source
April 2001
10 Reads

Dietary trial in prostate cancer: Early experience and implications for clinical trial design.

Urology 2001 Apr;57(4 Suppl 1):200-1

Preventive Medicine Research Institute, Sausalito, California, USA.

Much epidemiologic and case-controlled evidence suggests that diet may be a modifier of prostate cancer risk. However, the role of dietary modification in men known to have prostate cancer is a matter of some debate. To elucidate the effect of diet and comprehensive lifestyle changes on cancer risk, we are conducting a randomized, prospective clinical trial on men with clinically localized prostate cancer who have selected "watchful waiting" as primary therapy. Read More

View Article

Download full-text PDF

Source
April 2001
7 Reads

Prostate cancer prevention agent development: Criteria and pipeline for candidate chemoprevention agents.

Urology 2001 Apr;57(4 Suppl 1):56-63

Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Epidemiologic data suggest that prostate cancer morbidity and mortality ought to be preventable. New insights into the molecular pathogenesis of prostate cancer offer new opportunities for the discovery of prostate cancer chemoprevention drugs and new challenges for their development. Established pathways that lead to US Food and Drug Administration (FDA) approval of drugs for advanced prostate cancer may not be appropriate for the development of drugs for prostate cancer chemoprevention. Read More

View Article

Download full-text PDF

Source
April 2001
10 Reads
  • Page 1 of 1